Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform
The technology can be used in applications ranging from oncology to vaccines
Particle Sciences, a drug delivery contract development and manufacturing organisation (CDMO), has received a patent that gives the Bethlehem, PA-based company the legal right to use the technology incorporated into its SATx platform, which covers several structures that combine nanoparticles with surface bound large molecules.
The technology can be used in applications ranging from oncology to vaccines.
Particle Sciences' CEO Mark Mitchnick, said this is 'one more significant step' in building its drug delivery intellectual property portfolio. Using the SATx platform enables the company to offer 'a real alternative to typical ADC approaches', which can be rapidly prototyped and does not require the use of any new chemical entities.
Robert Becker, Vice President Biopharmaceutical Sales and Business Development, added: 'Particle Sciences has made a significant investment in both the formulation and analytic support of biologics. The SATx technology is a disruptive nanoparticle platform that gives our clients new options for improving the potency, safety, and utility of both large and small molecule therapeutics that cannot be found elsewhere. For clients looking to leverage their new biopharmaceuticals and vaccines, and those seeking to develop "bio-betters" the SATx platform should be seriously considered and evaluated.'